Skip to content

A trial to study the effect of a psychotherapy treatment for PTSD resulting from childhood trauma

Imagery Rescripting for Childhood Trauma related PTSD: A Multiple baseline study - NIL

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/09/073384
Enrollment
20
Registered
2024-09-04
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F431- Post-traumatic stress disorder (PTSD)

Interventions

Intervention1: Imagery Rescripting: Imagery Rescripting involves the individual imagining traumatic experiences with alternate outcomes, thus attempting to fulfil the core unmet needs. This process fa

Sponsors

National Institute of Mental Health and Neurosciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Individuals with a primary diagnosis of PTSD (according to DSM-5 criteria) as assessed by Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) and those who obtain a score of 33 and above on Post Traumatic Stress Disorder Checklist (PCL-5) or Individuals with a primary diagnosis of CPTSD (according to ICD 11 criteria) Individuals having experienced the worst traumatic event (defined according to the DSM-5) before the age of 16 and agree that this trauma will be the focus of treatment. Individuals belonging to the age group of 18-60 years Individuals who have undergone psychological interventions for PTSD but continue to fulfill the criteria for the diagnosis of PTSD (Score of 33 and above on PCL-5) Individuals who can read and write English.

Exclusion criteria

Exclusion criteria: Individuals with schizophrenia, bipolar disorder with current episode mania/ severe depression, current substance use/substance dependence/harmful use not in remission for at least 3 months except nicotine use Individuals with an organic brain disorder, neurodevelopmental disorders, or intelligence below the average category Individuals with severe symptoms of axis I disorders that might interfere with their engagement in therapy Individuals with acute suicidal risk or self-harm Individuals with ongoing trauma

Design outcomes

Primary

MeasureTime frame
PTSD Symptom severity as assessed by PCL-5Timepoint: 5 timepoints- Before baseline, After Baseline, before treatment, after treatment, at follow up which is 3 months after the treatment phase.

Secondary

MeasureTime frame
AngerTimepoint: 5 timepoints- Before baseline, After Baseline, before treatment, after treatment, at follow up which is 3 months after the treatment phase.;AnxietyTimepoint: 5 timepoints- Before baseline, After Baseline, before treatment, after treatment, at follow up which is 3 months after the treatment phase.;DepressionTimepoint: 5 timepoints- Before baseline, After Baseline, before treatment, after treatment, at follow up which is 3 months after the treatment phase.;Emotional regulationTimepoint: 5 timepoints- Before baseline, After Baseline, before treatment, after treatment, at follow up which is 3 months after the treatment phase.;GuiltTimepoint: 5 timepoints- Before baseline, After Baseline, before treatment, after treatment, at follow up which is 3 months after the treatment phase.;PTSD related cognitionsTimepoint: 5 timepoints- Before baseline, After Baseline, before treatment, after treatment, at follow up which is 3 months after the treatment phase.;ShameTimepoint: 5 timepoints- Before baseline, After Baseline, before treatment, after treatment, at follow up which is 3 months after the treatment phase.;Well-beingTimepoint: 5 timepoints- Before baseline, After Baseline, before treatment, after treatment, at follow up which is 3 months after the treatment phase.

Countries

India

Contacts

Public ContactAnju S Nair

National Institute of Mental Health and Neurosciences

anjusnairresearch2@gmail.com8281558398

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026